Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Graves’ Disease After Treatment With Alemtuzumab for Multiple Sclerosis
source: Hormones : International Journal of Endocrinology and Metabolism
year: 2015
authors: Tsourdi E, Gruber M, Rauner M, Blankenburg J, Ziemssen T, Hofbauer LC
summary/abstract:Context:
Alemtuzumab, a humanized monoclonal antibody against CD52, is effective in the treatment of early relapsing-remitting multiple sclerosis (MS). Common adverse effects include an acute-phase reaction, infections and autoimmune diseases, including thyroid disorders.
Setting:
Patients from two phase 3 trials (CARE MS 1 and 2, n=15) were studied in a clinical research center.
Patients:
Five out of fifteen patients developed severe Graves’ disease after a mean of 32 months following the first alemtuzumab treatment.
Main Outcome Measures:
Thyroid function tests and thyroid antibodies were assessed. In addition, endocrine tests and measurement of antibodies indicative of autoimmunity were performed.
Results:
Of the five patients developing Graves’ disease, four patients were initially treated with antithyroid drugs, whereas the fifth patient had mild and self-limiting hyperthyroidism. Of the four patients treated with antithyroid drugs, one is currently under medical treatment in a dose-reducing regimen, whereas three patients underwent near-total thyroidectomy 2, 12 and 16 months later. Two patients developed endocrine ophthalmopathy. Pituitary, adrenal and gonadal hormones were normal in all patients. While four out of five patients were positive for several other autoantibodies, none developed other autoimmune diseases.
Conclusion:
Since autoimmune thyroid disease is common after alemtuzumab treatment for MS, pretreatment screening and careful follow-up may allow for early diagnosis and treatment.
DOI: 10.14310/horm.2002.1501
read more full text
myBinderRelated Content
-
A Prospective Study of the Effects of Radioiodine Therapy for Hyperthyroidism in Patients With Minimally Active Grav...Context: Radioiodine is an effective an...
-
Reversible Pulmonary Hypertension and Clinical Right Heart Failure Associated With Graves’ DiseaseBackground: Heart failure is typically ...
-
Increased Cancer Incidence After Radioiodine Treatment for HyperthyroidismBackground: Concerns remain about risk ...
-
Hyperthyroidism and Your HeartHyperthyroidism occurs when your thyroid...
-
Hyperthyroidism and Graves’ DiseaseWhat is the Thyroid? The thyroid is a s...
-
Hyperthyroidism OverviewHyperthyroidism is known as overactive t...
-
Increased Cardiovascular Mortality and Morbidity in Patients Treated for Toxic Nodular Goiter Compared to GravesR...Background: Previous research has sugge...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google